SGLT2 inhibitors were designed as drugs for patients with diabetes that interfere with renal glucose and sodium reabsorption. The EMPEROR-reduced and DAPA-HF trials showed that SGLT2i treatment led to a significant reduction in the combined endpoint of cardiovascular death and hospitalizations in patients with heart failure with a reduced ejection fraction independent of diabetes status \([1, 2]\). However, the mechanisms responsible for these effects remain largely unexplored and clinical observations assessing heart function or hemodynamic status of those patients remain scarce.

A key feature of heart failure is inadequate cardiac output resulting in congestion and secondary pulmonary hypertension \([3]\). Higher pulmonary artery pressures predict HF symptoms, unplanned hospitalizations and mortality \([4, 5]\). Therefore, we analyzed the effect of SGLT2i on PA pressures in patients with severe heart failure regardless of ejection fraction. For this purpose, we analyzed data recorded by the CardioMEMS system, a remote sensor which transmits ambulatory recorded pulmonary artery pressures.

This was a retrospective case-series of ambulatory HFrEF or HFpEF patients who had previously received a CardioMEMS device, in whom either Dapagliflozin or Empagliflozin was initiated at the discretion of the treating physician. Hemodynamic data were abstracted from the medical record. PAP readings were collected daily starting 4 weeks prior to SGLT2i initiation for up to 10 weeks following initiation of treatment with SGLT2i. Patient records were audited to verify that other interventions that might have influenced PAP measurements (e.g., addition of new diuretic drugs and change in diuretic dose) had not occurred during the observation period.

All patients were on stable guideline-directed medical therapy for at least three months prior to SGLT2i treatment initiation. Adjustment of standard therapies was permitted if clinically indicated. Patients were excluded if they had initiation of \(\beta\)-blockers, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, or valsartan/sacubitril within three months before SGLT2i initiation.

Hemodynamic data pre and post SGL2 initiation were compared via Wilcoxon signed-rank testing and linear regression analysis was employed. All patients provided written informed consent for participation in this single center registry (NCT03020043). The study complies with the Declaration of Helsinki and was approved by the local ethics committee.

Statistical significance was assumed if \(P < 0.05\). Statistical analysis was performed with Graph Pad Prism Vers. 8.2.0.

In the present cohort, 17 patients with advanced chronic heart failure were analyzed. All patients underwent implantation of a CardioMEMS system between 2015 and 2020. SGLT2 inhibitors were initiated either as diabetes therapy or as a heart failure drug. 8 of 17 patients had diabetes. 13 patients received dapagliflozin \((1 \times 10 \text{ mg/d})\), four patients were treated with empagliflozin \((1 \times 10 \text{ mg/d})\). Baseline characteristics and medication of all patients are shown in Table 1. PAP values were recorded on a daily base in the 30-day period prior to initiation of SGL2i treatment until 70 days (10 weeks) after start of SGLT2 intake. After 10 weeks, we observed significant reductions of systolic PAP \((-3.59 \pm 1.55 \text{ mmHg}; \ P = 0.034\)\), mean PAP
Inclusion of PA-Pressures as an additional treatment target substantially reduced hospitalizations for heart failure in 75% of patients with HFrEF and 35% of patients with HfPEF [3], is associated with higher frequency in PA pressures occurs after addition of an SGLT2i to optimal medical background therapy. All PAP values, Fig. 1D).

Our results add to a smaller observation which describes lower PA pressures within 1 week after initiation of dapa-gliflozin in 9 patients assessed by remote PA-pressure sensors[8] and confirm data from a small, randomized study, in which 33 patients who started empagliflozin recorded lower PA pressures within a 12-week timespan [9].

The mechanisms contributing to the beneficial effect of SGLT2i in heart failure remain elusive. Possible mechanisms for the effects observed in our study suggest either direct effects on the heart, vasodilation of the pulmonary vasculature, a direct natriuretic/diuretic effect or a combination of those as possible causes for improved hemodynamics in patients with HF. Indeed, it was shown that empagliflozin might improve diastolic function of human myocardium, while systolic contractility was not affected [10]. Correspondingly, empagliflozin significantly reduced the PCWP after 12 weeks of treatment in patients with HFrEF in a small clinical trial [11]. Moreover, experimental studies describe attenuation of vascular dysfunction and enhanced endothelium-dependent vasorelaxation, mechanisms, which are relevant in pulmonary hypertension due to heart failure [12]. Finally, two randomized trials examining the effects of empagliflozin on cardiac remodeling in patients with HFrEF reported improvements of left ventricular volumes and function after 6 months of treatment [13, 14]. This might have been driven by either a direct effect of SGLT2i on the myocardium or an improvement of volume status. The effects observed in the present manuscript developed rather early, suggesting that a diuretic effect at least in part contributed to improved hemodynamics after initiation of an SGLT2i. Indeed, a small clinical study showed that empagliflozin causes natriuresis and reduces blood volume. This mechanism does not come with the cost of neurohumoral activation, reduction in kidney function or electrolyte wasting, which are common side effects of classical diuretics [15]. Off note, dosage of diuretics did not change significantly over the observation period in our study, which corroborates data from the DAPA-HF trial [16]. In addition, the reduction of PA-Pressures observed in our cohort occurred in patients with optimal medical background therapy. All patients were treated with betablockers and RAAS-blockade, and 76% of all patients were treated with an aldosterone receptor antagonist.

This study is a small, single center, non-randomized trial. However, it extends previous observations and frequent assessment of PA pressures allowed the generation of significant data. In summary, an early and persistent fall in PA pressures occurs after addition of an SGLT2i to optimal medical therapy in patients with heart failure, which, therefore, should be considered as a first line heart failure treatment.

Table 1 Baseline characteristics

| Demographics                         | Medical history             | Baseline laboratory values | Baseline Heart Failure Medication |
|---------------------------------------|------------------------------|----------------------------|----------------------------------|
| Age (y)                               | HFrEF, n (%)                | nt-proBNP (pg/ml)         | Betablocker, n (%)                |
|                                       | 67.18 ± 3.09                | 1916 ± 1050              | 17 (100)                         |
| Male, n (%)                           | 17 (100)                    | Creatinine (mg/dl)        | ARNI, n (%)                      |
|                                       |                              | 1.42 ± 0.11              | 15 (88.2)                        |
| Medical history                       | HfPEF, n (%)                |                         | ACE inhibitor, n (%)             |
|                                       | 15 (88.2)                   |                           | 2 (11.8)                         |
| Ischemic heart disease, n (%)         | 2 (11.8)                    |                           | MRA, n (%)                       |
| Diabetes mellitus, n (%)              | 15 (88.2)                   |                           | 13 (76.4)                        |
| NYHA class                            | 8 (47.1)                    |                           | Torasemide, n (%)                |
|                                       | 2.56 ± 0.12                 |                           | 17 (100)                         |
| Baseline laboratory values            |                              |                           | Torasemide dose                  |
| nt-proBNP (pg/ml)                     |                              |                           | 30 days prior to SGLT2i start (mg) |
| Creatinine (mg/dl)                    |                              |                           | 45.29 ± 12.75                    |
| Baseline (mg)                         |                              |                           | Baseline (mg)                    |
|                                     |                              |                           | 45.59 ± 10.2                     |
| 30 days after SGLT2i start (mg)       |                              |                           | 41.18 ± 12.24; p = 0.88          |
| 70 days after SGLT2i start (mg)       |                              |                           |                                  |

Values are shown as absolute numbers (percentages) and mean ± SEM

(−3.06 ± 1.22 mmHg; P = 0.014), and diastolic pulmonary artery pressure (−2.65 ± 0.98 mmHg; P = 0.008; Fig. 1A–C). Off note, dosage of loop diuretics did not change significantly in the observation period (Table 1). Other heart failure medications were not relevantly changed in the 30-day period prior to SGLT2i start and in the 70 days after drug initiation. Interestingly, PAP changes occurred already after 3 weeks of treatment and increased over time (P < 0.001 for all PAP values, Fig. 1D).

In this single-center, non-randomized observational study, the addition of a SGLT2i to optimal medical therapy consisting of an ARNI, betablocker and aldosterone-antagonist significantly decreased PA-pressures in patients with heart failure. This effect commenced after 3 weeks and increased over time, reaching 3 mmHg after 10 weeks. The results were consistent for PA diastolic, systolic and mean pressures. The presence of pulmonary hypertension, which occurs in 40–75% of patients with HFrEF and 35–80% of patients with HfPEF [3], is associated with higher frequency of heart failure hospitalizations and increased mortality [5]. Inclusion of PA-Pressures as an additional treatment target substantially reduced hospitalizations for heart failure in both HfPEF and HFrEF [6, 7].

Our results add to a smaller observation which describes lower PA pressures within 1 week after initiation of dapagliflozin in 9 patients assessed by remote PA-pressure sensors[8] and confirm data from a small, randomized study, in which 33 patients who started empagliflozin recorded lower PA pressures within a 12-week timespan [9].

The mechanisms contributing to the beneficial effect of SGLT2i in heart failure remain elusive. Possible mechanisms for the effects observed in our study suggest either direct effects on the heart, vasodilation of the pulmonary vasculature, a direct natriuretic/diuretic effect or a combination of those as possible causes for improved hemodynamics in patients with HF. Indeed, it was shown that empagliflozin might improve diastolic function of human myocardium, while systolic contractility was not affected [10]. Correspondingly, empagliflozin significantly reduced the PCWP after 12 weeks of treatment in patients with HFrEF in a small clinical trial [11]. Moreover, experimental studies describe attenuation of vascular dysfunction and enhanced endothelium-dependent vasorelaxation, mechanisms, which are relevant in pulmonary hypertension due to heart failure [12]. Finally, two randomized trials examining the effects of empagliflozin on cardiac remodeling in patients with HFrEF reported improvements of left ventricular volumes and function after 6 months of treatment [13, 14]. This might have been driven by either a direct effect of SGLT2i on the myocardium or an improvement of volume status. The effects observed in the present manuscript developed rather early, suggesting that a diuretic effect at least in part contributed to improved hemodynamics after initiation of an SGLT2i. Indeed, a small clinical study showed that empagliflozin causes natriuresis and reduces blood volume. This mechanism does not come with the cost of neurohumoral activation, reduction in kidney function or electrolyte wasting, which are common side effects of classical diuretics [15]. Off note, dosage of diuretics did not change significantly over the observation period in our study, which corroborates data from the DAPA-HF trial [16]. In addition, the reduction of PA-Pressures observed in our cohort occurred in patients with optimal medical background therapy. All patients were treated with betablockers and RAAS-blockade, and 76% of all patients were treated with an aldosterone receptor antagonist.

This study is a small, single center, non-randomized trial. However, it extends previous observations and frequent assessment of PA pressures allowed the generation of significant data. In summary, an early and persistent fall in PA pressures occurs after addition of an SGLT2i to optimal medical therapy in patients with heart failure, which, therefore, should be considered as a first line heart failure treatment.
Acknowledgements We thank Kathleen Mantzsch and Meaza Tekeste (Heart Failure Nurses) for excellent study support.

Funding Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** On behalf of all authors, the corresponding author states that there is no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are
Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 7:2071–2073

9. Nassif ME, Qintar M, Windsor SL, Jermy R, Shavell LE, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN (2021) Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation 143:1673–1686

10. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács A, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Limthout S, Tschöpe C, Streckfuss-Bömeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S (2018) Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail 20:1690–1700

11. Omar M, Jensen J, Frederiksen PH, Kistorp C, Vildebaek L, Poulsen MK, Möller S, Ali M, Gustafsson F, Köber L, Borlaug BA, Schou M, Möller JE (2020) Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 76:2740–2751

12. Alshnbari AS, Millar SA, O’Sullivan SE, Idris I (2020) Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies. Diabetes Ther 11:1947–1963

13. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Maculoso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ, EMPA-TROPSM ATRU-4I (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77:243–255

14. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KE, Dreibschag J, Labinjoh C, Lang NN, Lennie V, McCrackie A, Murphy CL, Petrie CJ, Petrie JR, Speirts IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JV, Jhund PS, Petrie MC, Sattar N (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143:516–525

15. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello P, Bellumkonda L, Cox Z, Collins S, Jhund PS, McMurray JV, Jhund PS, Petrie MC, Sattar N (2021) Randomized trial of empagliflozin in heart failure: diuretic and cardiorespiratory effects. Circulation 142:1028–1039

16. Jackson AM, Dewan P, Anand IS, Bélohlávek J, Böhm M, Boulton DW, Chopra VK, DeMets DL, Docherty KE, Dukát A, Greasley PJ, Inzucchi SE, Køber L, Ljungman CEA, Martinez FA, Meara E, O’Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JV (2020) Dapagliflozin and diuretic use in patients with heart failure and preserved ejection fraction in DAPA-HF. Circulation 142:1040–1054

References

1. McMurray JJV, Solomon SD, Inzucchi SE, Köber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bélohlávek J, Böhm M, Chiarn CE, Chopra VK, de Boer RA, Desai AS, Dicz M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KE, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF TCAI (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008

2. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tatsutsu H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuqiire J, Giannetti N, Jannsens S, Zhang J, Gonzalez Juantejey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nichols SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced DTI (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 381:1413–1424

3. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Van Noordegraaf A, Vachiery JL (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954

4. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, Jiang R, Roger VL (2012) Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 59:222–231

5. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Arandia JM, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118:1433–1441

6. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelaguru S, Raval N, Kruger S, Weiner S, Shavell J, Jeffries B, Yadav JS, CHAMPION TSG (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666

7. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7:935–944

8. Mullens W, Martens P, Forouzan O, Dauw J, Vercammen J, Luwel E, Ceeyssens W, Kockaerts V, Ameloot K, Dupont M (2020) Included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Springer